Insmed (INSM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., to serve until the 2029 Annual Meeting of Shareholders.
Advisory vote on the 2025 compensation of named executive officers.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Other business may be considered as may properly come before the meeting or any adjournment or postponement.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals presented.
Executive compensation and say-on-pay
Shareholders will cast an advisory vote on the 2025 compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Insmed
- Record 2025 revenues, major product approvals, and strong governance set the stage for continued growth.INSM
Proxy filing1 Apr 2026 - Late-stage pipeline and strong launches position for major growth and label expansions.INSM
Investor presentation25 Mar 2026 - ARIKAYCE improved symptoms and culture conversion, supporting label expansion in MAC lung disease.INSM
Study result23 Mar 2026 - Major clinical milestones and strong commercial execution drive growth across key therapeutic areas.INSM
Leerink Global Healthcare Conference 202610 Mar 2026 - Exceptional Q4 launch sets stage for sustained growth and major pipeline-driven expansion.INSM
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2026 revenues guided to at least $1.45B, driven by BRINSUPRI and ARIKAYCE growth.INSM
Q4 202519 Feb 2026 - Multiple late-stage assets and strong launches position for significant growth in 2026.INSM
Investor presentation19 Feb 2026 - Brensocatib's phase 3 success and ARIKAYCE's growth drive multi-billion-dollar expansion.INSM
51st Nasdaq London Investor Conference3 Feb 2026 - Q2 revenue up 17% to $90.3M; brensocatib advances toward NDA and commercial launch.INSM
Q2 20242 Feb 2026